However, at the 4-week follow-up, the fold difference in the levels of IL-6 (14.5 pg/mL vs 5.6 pg/mL, p < 0.001), IL-17 (14.9 pg/mL vs 3.8 pg/mL, p < 0.001), and IL-21 (19.5 pg/mL vs 4.4 pg/mL, p < 0.001) between MG patients and HCs were minimized (Figures 6A, B). This evidence concerns the gene IL21 and myasthenia gravis.